Workshop on Key Issues in Improving the Accessibility to Drugs in Developing Countries

June 2, 2003

The World Bank
1818 H Street, NW, Washington, D.C.
Conference room: I1-200.

Background Papers Presented at Workshop

Scope and Purpose:

This workshop is part of a World Bank consultation process on The Role of the Generics and Local Industry in Attaining the MDGs in Pharmaceuticals and Vaccines. The workshop objectives are to explore some areas that in the preparatory meetings were identified as deserving an especial attention, because there seemed to be limited information on the situation and problems and no evidence and consensus on how best to approach them.


8.30-9.00 Introductory session:

9.00-11.00 Session 1: Local production in developing countries

Organizer: Warren Kaplan, Boston University
Chair: Ilyse Zable, IFC

The purpose of the session is to identify opportunities for the World Bank and the IFC to support efficient and sustainable production of quality drugs. The session will try to identify our knowledge on pharmaceutical production in developing countries, as well as the existing gaps. It will also address the complexities of pharmaceutical production in order to assess what type of production can be carried out efficiently in developing countries and try to set a research agenda on local production issues.

11.15-12.30 Session 2: Differential pricing: theory, experiences and proposals

Organizer: Juan Rovira, The World Bank
Chair: F.M. Scherer, Princeton University

The purpose of the session is to review the theoretical framework of differential pricing, as well as the evidence on its application and effects in actual cases. The session will also review normative approaches and proposals for equity pricing as a way to improving access to drugs in developing countries.

12.30-1.30 Lunch

1.30-5.00 Session 3: Compensation and Compulsory Licenses: implementing the Doha Declaration and advancing the UN Millennium Development Goals

Organizer: Jamie Love, Consumer Project on Technology.

The session will consist of two panels, both addressing the same question: How does one reconcile the Doha Declaration on TRIPS to ensure access to medicines for all with the TRIPS obligations on compensation to patent owners when non-voluntary use of a patent is authorized?

1.30-3.00 Panel 1

Chair: Ruldolf V. Van Puymbroeck, Lead Counsil, The World Bank.

3.30-5.00 Panel 2

Chair: Yolanda Tayler, Senior Procurement Specialist, The World Bank

Due to space constraints, please confirm attendance to Akosua Dakwa,, phone 202 458 2283.

The sessions will be video-recorded and made available for public access at B-SPAN, the World Bank's web casting station on development issue.

Return to: CPTech Home -> CPTech Events Page | IP and Healthcare